DEF: Arvinas, Inc. Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Arvinas, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 25, 2025, featuring director elections, executive compensation advisory vote, and auditor ratification.

Summary

• Arvinas, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 25, 2025, at 8:30 a.m. Eastern Time.
• Stockholders of record as of April 28, 2025, are eligible to vote on key proposals.
• The agenda includes the election of three Class I directors for terms expiring in 2028, an advisory vote on executive compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the approval of the other proposals.
• Proxy materials are available online, and stockholders can vote via the internet, telephone, or mail.

Sentiment

Score: 7

Explanation: The document is factual and procedural, outlining the details of the upcoming annual meeting. The sentiment is neutral to positive, reflecting standard corporate governance practices and a generally stable outlook.

Positives

• The company is providing access to proxy materials via the internet to reduce paper and mailing costs.
• The virtual meeting format is expected to enable greater stockholder attendance and participation from any location around the world.
• The Board of Directors is actively involved in the oversight of risks that could affect the company.
• The company has adopted a Dodd-Frank Compensation Recovery Policy, or Clawback Policy, in accordance with Rule 10D-1 of the Exchange Act and Nasdaq listing standards, which is applicable to all of our current or former executive officers, or the Covered Persons.

Negatives

• Sean Cassidy stepped down as Chief Financial Officer, Treasurer and principal financial officer effective February 29, 2024.
• The company's overall corporate goals had been achieved at a level of 107.5%, however, as part of our overall commitment to our employees, we funded a special bonus pool of 3.5% from the overall bonus pool of 107.5%. As such, the bonuses awarded to all employees, including our named executive officers, for 2024 are based on a corporate goal achievement level of 104.0%.

Risks

• The company faces a number of risks, including those described under Risk Factors in the 2024 Annual Report.
• Risk is inherent with every business and how well a business manages risk can ultimately determine its success.

Future Outlook

The company plans to explore initiation of a more formal engagement process to obtain regular feedback from its stockholders on executive compensation, corporate governance and other matters important to stockholders.

Management Comments

• The board of directors recommends that you vote FOR each of the Class I director nominees (Proposal 1), and FOR each of Proposals 2 and 3.
• By order of the Board of Directors, /s/ John Houston, Ph.D. John Houston, Ph.D. Chairperson, President and Chief Executive Officer

Industry Context

This announcement is typical for publicly traded companies as they prepare for their annual meetings, ensuring compliance with SEC regulations and corporate governance best practices.

Comparison to Industry Standards

• The peer group used for compensation benchmarking includes Alector, Inc., Denali Pharmaceuticals, Inc., Revolution Medicines, Inc., Arcus Biosciences, Inc., Fate Therapeutics, Inc., SpringWorks Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Intellia Therapeutics, Inc., Xencor, Inc., Cerevel Therapeutics, Inc., Mirati Therapeutics, Inc., Zentalis Pharmaceuticals, Crinetics Pharmaceuticals, REGENXBIO, Inc., Deciphera Pharmaceuticals, and Relay Therapeutics.
• Aon focused on developing a peer group that comprised companies operating in the biopharmaceutical industries, captured comparable companies in terms of market capitalization, revenue, employee size and stage of development, and allowed for sufficient room for the company to grow.
• The 2024 Peer Group represents a group of pre-commercial, later stage (companies in Phase 3 development and companies in the stages of submitting new-drug applications), oncology or neurology-focused biopharmaceutical/biotechnology companies, with a median market capitalization of $1,631.8 million and a median of 314 employees at the time of review.

Management Changes

Corporate Governance

Legal Proceedings

• Codiak BioSciences, Inc., where Ms. Bain previously served as Chief Financial Officer, filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in March 2023.

Related Party Transactions

• The proxy statement describes employment arrangements with named executive officers.
• The company has entered into indemnification agreements with all of its directors and executive officers.

Stakeholder Impact

• Stockholders have the opportunity to vote on key proposals that will shape the company's direction.
• Employees are impacted by changes in executive compensation and management structure.
• The company's performance and governance practices affect investor confidence and market valuation.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 25, 2025, and announce the voting results.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Board of Directors, Executive Compensation, Director Election, Deloitte & Touche LLP, Corporate Governance, Arvinas